All eyes on psychedelic drugmakers as Definium, Compass near major catalysts

Data ReadoutPositive

AI Analysis

Summary

Definium Therapeutics is preparing to announce anxiety trial results for its single-dose LSD candidate, while Compass Pathways progresses its psilocybin program through a rolling FDA submission.

Outcome Details

Definium anxiety readout pending; Compass advancing psilocybin through rolling FDA filing

Importance:6/10

Sentiment:

0.30

psychedelicsLSDpsilocybinanxietyFDA filingclinical catalyst

Related Companies

$CMPS

Read the original article

Published by BioSpace on August 10, 2026 2:37 PM

Read Original